Abstract
BackgroundGiven the difficulty in preoperatively diagnosing lymph node metastasis, patients with Stage I–III non-small cell lung cancer (NSCLC) are likely to be included in the clinical N1 (cN1) group. However, better treatment options might be selected through further stratification. This study aimed to identify preoperative clinicopathological prognostic and stratification factors for patients with cN1 NSCLC.MethodsThis retrospective study evaluated 60 patients who were diagnosed with NSCLC during 2004–2014. Clinical nodal status had been evaluated using routine chest computed tomography (CT) and/or positron emission tomography (PET). To avoid biasing the fluorodeoxyglucose uptake values based on inter-institution or inter-model differences, we used only two PET systems (one PET system and one PET/CT system). Relapse-free survival (RFS) and overall survival (OS) were the primary study outcomes. The maximum standardized uptake value (SUVmax) was calculated for each tumor and categorized as low or high based on the median value. Patient sex, age, histology, tumor size, and tumor markers were also assessed.ResultsPoor OS was associated with older age (P = 0.0159) and high SUVmax values (P = 0.0142). Poor RFS was associated with positive carcinoembryonic antigen (CEA) expression (P = 0.0035) and high SUVmax values (P = 0.015). Multivariate analyses confirmed that poor OS was independently predicted by older age (hazard ratio [HR] = 2.751, confidence interval [CI]: 1.300–5.822; P = 0.0081) and high SUVmax values (HR = 5.121, 95% CI: 1.759–14.910; P = 0.0027). Furthermore, poor RFS was independently predicted by positive CEA expression (HR = 2.376, 95% CI: 1.056–5.348; P = 0.0366) and high SUVmax values (HR = 2.789, 95% CI: 1.042–7.458; P = 0.0410). The primary tumor’s SUVmax value was also an independent prognostic factor for both OS and RFS.ConclusionsFor patients with cN1 NSCLC, preoperative prognosis and stratification might be performed based on CEA expression, age, and the primary tumor’s SUVmax value. To enhance the prognostic value of the primary tumor’s SUVmax value, minimizing bias between facilities and models could lead to a more accurate prognostication.
Highlights
Given the difficulty in preoperatively diagnosing lymph node metastasis, patients with Stage I–III nonsmall cell lung cancer (NSCLC) are likely to be included in the clinical N1 group
For patients with clinical N1 (cN1) NSCLC, preoperative prognosis and stratification might be performed based on carcinoembryonic antigen (CEA) expression, age, and the primary tumor’s Maximum standardized uptake value (SUVmax) value
We identified 78 patients (8.6%) with cN1 NSCLC based on preoperative computed tomography (CT) and/or positron emission tomography (PET), 11 patients were excluded because they were diagnosed at other facilities
Summary
Given the difficulty in preoperatively diagnosing lymph node metastasis, patients with Stage I–III nonsmall cell lung cancer (NSCLC) are likely to be included in the clinical N1 (cN1) group. Given the difficulty in preoperatively diagnosing lymph node metastasis, all patients with Stage I–III disease are likely to be provisionally included in the cN1 group. This can lead to suboptimal treatment based on a single treatment strategy in at least some of these cases. The present study aimed to retrospectively evaluate cN1 NSCLC cases in an attempt to identify preoperative clinicopathological factors that might predict the prognosis and guide the selection of optimal treatment strategies
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.